Your browser doesn't support javascript.
loading
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Dejnirattisai, Wanwisa; Huo, Jiandong; Zhou, Daming; Zahradník, Jirí; Supasa, Piyada; Liu, Chang; Duyvesteyn, Helen M E; Ginn, Helen M; Mentzer, Alexander J; Tuekprakhon, Aekkachai; Nutalai, Rungtiwa; Wang, Beibei; Dijokaite, Aiste; Khan, Suman; Avinoam, Ori; Bahar, Mohammad; Skelly, Donal; Adele, Sandra; Johnson, Sile Ann; Amini, Ali; Ritter, Thomas; Mason, Chris; Dold, Christina; Pan, Daniel; Assadi, Sara; Bellass, Adam; Omo-Dare, Nikki; Koeckerling, David; Flaxman, Amy; Jenkin, Daniel; Aley, Parvinder K; Voysey, Merryn; Clemens, Sue Ann Costa; Naveca, Felipe Gomes; Nascimento, Valdinete; Nascimento, Fernanda; Fernandes da Costa, Cristiano; Resende, Paola Cristina; Pauvolid-Correa, Alex; Siqueira, Marilda M; Baillie, Vicky; Serafin, Natali; Ditse, Zanele; Da Silva, Kelly; Madhi, Shabir; Nunes, Marta C; Malik, Tariq; Openshaw, Peter Jm; Baillie, J Kenneth; Semple, Malcolm G.
Afiliación
  • Dejnirattisai W; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Huo J; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Zhou D; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Zahradník J; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
  • Supasa P; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Liu C; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Duyvesteyn HME; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Ginn HM; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
  • Mentzer AJ; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Tuekprakhon A; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Nutalai R; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Wang B; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Dijokaite A; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Khan S; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Avinoam O; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Bahar M; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Skelly D; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Adele S; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Johnson SA; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Amini A; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Ritter T; Peter Medawar Building for Pathogen Research, Oxford, UK.
  • Mason C; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Dold C; Peter Medawar Building for Pathogen Research, Oxford, UK.
  • Pan D; Peter Medawar Building for Pathogen Research, Oxford, UK.
  • Assadi S; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Bellass A; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
  • Omo-Dare N; Peter Medawar Building for Pathogen Research, Oxford, UK.
  • Koeckerling D; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Flaxman A; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Jenkin D; NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Voysey M; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust.
  • Clemens SAC; Department of Respiratory Sciences, University of Leicester.
  • Naveca FG; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust.
  • Nascimento V; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust.
  • Nascimento F; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust.
  • Fernandes da Costa C; Medical Sciences Division, University of Oxford.
  • Resende PC; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Pauvolid-Correa A; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Siqueira MM; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Baillie V; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Serafin N; Institute of Global Health, University of Siena, Siena, Brazil; Department of Paediatrics, University of Oxford, Oxford, UK.
  • Ditse Z; Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.
  • Da Silva K; Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.
  • Madhi S; Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.
  • Nunes MC; Fundação de Vigilância em Saúde do Amazonas, Manaus, Amazonas, Brazil.
  • Malik T; Laboratorio de vírus respiratórios- IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Openshaw PJ; Laboratorio de vírus respiratórios- IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Baillie JK; Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, United States.
  • Semple MG; Laboratorio de vírus respiratórios- IOC/FIOCRUZ, Rio de Janeiro, Brazil.
bioRxiv ; 2021 Dec 22.
Article en En | MEDLINE | ID: mdl-34981049
ABSTRACT
On the 24 th November 2021 the sequence of a new SARS CoV-2 viral isolate spreading rapidly in Southern Africa was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially reduced or fail to neutralize. Titres against Omicron are boosted by third vaccine doses and are high in cases both vaccinated and infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of a large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses, combining mutations conferring tight binding to ACE2 to unleash evolution driven by immune escape, leading to a large number of mutations in the ACE2 binding site which rebalance receptor affinity to that of early pandemic viruses.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido